一种表达蜱传脑炎病毒 prME 的重组改良安卡拉牛痘病毒能为小鼠提供针对 TBEV 感染的完全保护。
A recombinant Modified Vaccinia virus Ankara expressing prME of tick-borne encephalitis virus affords mice full protection against TBEV infection.
机构信息
Research Center for Emerging Infections and Zoonoses, University of Veterinary Medicine Hannover, Foundation, Hannover, Germany.
Department of Pathology, University of Veterinary Medicine Hannover, Foundation, Hannover, Germany.
出版信息
Front Immunol. 2023 Apr 21;14:1182963. doi: 10.3389/fimmu.2023.1182963. eCollection 2023.
INTRODUCTION
Tick-borne encephalitis virus (TBEV) is an important human pathogen that can cause a serious disease involving the central nervous system (tick-borne encephalitis, TBE). Although approved inactivated vaccines are available, the number of TBE cases is rising, and breakthrough infections in fully vaccinated subjects have been reported in recent years.
METHODS
In the present study, we generated and characterized a recombinant Modified Vaccinia virus Ankara (MVA) for the delivery of the pre-membrane (prM) and envelope (E) proteins of TBEV (MVA-prME).
RESULTS
MVA-prME was tested in mice in comparison with a licensed vaccine FSME-IMMUN® and proved to be highly immunogenic and afforded full protection against challenge infection with TBEV.
DISCUSSION
Our data indicate that MVA-prME holds promise as an improved next-generation vaccine for the prevention of TBE.
简介
蜱传脑炎病毒（TBEV）是一种重要的人类病原体，可导致涉及中枢神经系统的严重疾病（蜱传脑炎，TBE）。尽管已批准使用灭活疫苗，但 TBE 病例的数量仍在上升，近年来已报告在完全接种疫苗的受试者中出现突破性感染。
方法
在本研究中，我们生成并鉴定了一种用于递送 TBEV 前膜（prM）和包膜（E）蛋白的重组改良安卡拉痘苗病毒（MVA）（MVA-prME）。
结果
与已批准的疫苗 FSME-IMMUN®相比，MVA-prME 在小鼠中进行了测试，结果证明其具有高度的免疫原性，并能完全抵御 TBEV 感染的挑战。
讨论
我们的数据表明，MVA-prME 有望成为预防 TBE 的新一代改良疫苗。
Zotero 插件